Return to homepagePandemic Pact

International randomized trial to evaluate unlicensed treatments for COVID-19 in hospitalized patients receiving conventional treatment for COVID offered in each hospital

  • Funded by National Institute of Health Carlos III [El Instituto de Salud Carlos III] (ISCIII)
  • Total publications:0 publications

Grant number: COV20_00612

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    N/A

  • Funder

    National Institute of Health Carlos III [El Instituto de Salud Carlos III] (ISCIII)

  • Principal Investigator

    Vicente Estrada, Antonio Portolés

  • Research Location

    Spain

  • Lead Research Institution

    Fundación para la Investigación Biomédica del Hospital Clínico San Carlos-IdISSC

  • Research Priority Alignment

    N/A

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Clinical trials for disease management

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Randomized Controlled Trial

  • Broad Policy Alignment

    Pending

  • Age Group

    Adults (18 and older)

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

International randomized trial of adaptive design to evaluate unlicensed treatments for COVID-19 in hospitalized patients receiving conventional treatment for COVID offered in each hospital. Adults> 18a hospitalized with laboratory confirmed COVID-19 with no contraindication to study drugs or reason for not participating will be included. They will be randomized to: conventional TTo or conventional Tto plus one of the tested drugs (Remdesivir, Chloroquine / OHchloroquine, Lopinavir + Ritonavir or Lopinavir / Ritonavir + Interferon). Included patients are followed daily for the duration of treatment.